RVMD.US Revolution Medicines Inc

Healthcare Biotechnology USA Stocks
162.69 USD
Close of Nov 18, 2026
69.50 224.31
Market cap
USD 35.2B
P/E
-
P/B
15.03x
ROE
-83.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RVMD.US undervalued?

Graham number

The Graham number of Revolution Medicines Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Revolution Medicines Inc fundamental analysis

No fundamental analysis for Revolution Medicines Inc yet.

Revolution Medicines Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Revolution Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-a…

Full company profile